Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Weight Watchers va-t-il survivre à la révolution des médicaments coupe-faim ? En France, WW va se délester de tous ses ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Starting January 1, the cost of the popular weight loss medication Wegovy will drop significantly in Israel—but only for its ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...